

Currently released so far... 12553 / 251,287
Browse latest releases
2010/12/01
2010/12/02
2010/12/03
2010/12/04
2010/12/05
2010/12/06
2010/12/07
2010/12/08
2010/12/09
2010/12/10
2010/12/11
2010/12/12
2010/12/13
2010/12/14
2010/12/15
2010/12/16
2010/12/17
2010/12/18
2010/12/19
2010/12/20
2010/12/21
2010/12/22
2010/12/23
2010/12/24
2010/12/25
2010/12/26
2010/12/27
2010/12/28
2010/12/29
2010/12/30
2011/01/01
2011/01/02
2011/01/04
2011/01/05
2011/01/07
2011/01/09
2011/01/10
2011/01/11
2011/01/12
2011/01/13
2011/01/14
2011/01/15
2011/01/16
2011/01/17
2011/01/18
2011/01/19
2011/01/20
2011/01/21
2011/01/22
2011/01/23
2011/01/24
2011/01/25
2011/01/26
2011/01/27
2011/01/28
2011/01/29
2011/01/30
2011/01/31
2011/02/01
2011/02/02
2011/02/03
2011/02/04
2011/02/05
2011/02/06
2011/02/07
2011/02/08
2011/02/09
2011/02/10
2011/02/11
2011/02/12
2011/02/13
2011/02/14
2011/02/15
2011/02/16
2011/02/17
2011/02/18
2011/02/19
2011/02/20
2011/02/21
2011/02/22
2011/02/23
2011/02/24
2011/02/25
2011/02/26
2011/02/27
2011/02/28
2011/03/01
2011/03/02
2011/03/03
2011/03/04
2011/03/05
2011/03/06
2011/03/07
2011/03/08
2011/03/09
2011/03/10
2011/03/11
2011/03/13
2011/03/14
2011/03/15
2011/03/16
2011/03/17
2011/03/18
2011/03/19
2011/03/20
2011/03/21
2011/03/22
2011/03/23
2011/03/24
2011/03/25
2011/03/26
2011/03/27
2011/03/28
2011/03/29
2011/03/30
2011/03/31
2011/04/01
2011/04/02
2011/04/03
2011/04/04
2011/04/05
2011/04/06
2011/04/07
2011/04/08
2011/04/09
2011/04/10
2011/04/11
2011/04/12
2011/04/13
2011/04/14
2011/04/15
2011/04/16
2011/04/17
2011/04/18
2011/04/19
2011/04/20
2011/04/21
2011/04/22
2011/04/23
2011/04/24
2011/04/25
2011/04/26
2011/04/27
2011/04/28
2011/04/29
2011/04/30
2011/05/01
2011/05/02
2011/05/03
2011/05/04
2011/05/05
2011/05/06
2011/05/07
2011/05/08
2011/05/09
2011/05/10
2011/05/11
2011/05/12
Browse by creation date
Browse by origin
Embassy Athens
Embassy Asuncion
Embassy Astana
Embassy Asmara
Embassy Ashgabat
Embassy Apia
Embassy Ankara
Embassy Amman
Embassy Algiers
Embassy Addis Ababa
Embassy Accra
Embassy Abuja
Embassy Abu Dhabi
Embassy Abidjan
Consulate Auckland
Consulate Amsterdam
Consulate Adana
American Institute Taiwan, Taipei
Embassy Bujumbura
Embassy Buenos Aires
Embassy Budapest
Embassy Bucharest
Embassy Brussels
Embassy Bridgetown
Embassy Bratislava
Embassy Brasilia
Embassy Bogota
Embassy Bishkek
Embassy Bern
Embassy Berlin
Embassy Belmopan
Embassy Belgrade
Embassy Beirut
Embassy Beijing
Embassy Banjul
Embassy Bangkok
Embassy Bandar Seri Begawan
Embassy Bamako
Embassy Baku
Embassy Baghdad
Consulate Barcelona
Embassy Copenhagen
Embassy Conakry
Embassy Colombo
Embassy Chisinau
Embassy Caracas
Embassy Canberra
Embassy Cairo
Consulate Curacao
Consulate Ciudad Juarez
Consulate Chennai
Consulate Casablanca
Consulate Cape Town
Consulate Calgary
Embassy Dushanbe
Embassy Dublin
Embassy Doha
Embassy Djibouti
Embassy Dili
Embassy Dhaka
Embassy Dar Es Salaam
Embassy Damascus
Embassy Dakar
Consulate Dubai
Embassy Helsinki
Embassy Harare
Embassy Hanoi
Consulate Ho Chi Minh City
Consulate Hermosillo
Consulate Hamilton
Consulate Hamburg
Consulate Halifax
Embassy Kyiv
Embassy Kuwait
Embassy Kuala Lumpur
Embassy Kinshasa
Embassy Kingston
Embassy Kigali
Embassy Khartoum
Embassy Kathmandu
Embassy Kampala
Embassy Kabul
Consulate Kolkata
Embassy Luxembourg
Embassy Luanda
Embassy London
Embassy Ljubljana
Embassy Lisbon
Embassy Lima
Embassy Lilongwe
Embassy La Paz
Consulate Lahore
Consulate Lagos
Mission USOSCE
Mission USNATO
Mission UNESCO
Embassy Muscat
Embassy Moscow
Embassy Montevideo
Embassy Monrovia
Embassy Minsk
Embassy Mexico
Embassy Mbabane
Embassy Maputo
Embassy Manila
Embassy Manama
Embassy Managua
Embassy Malabo
Embassy Madrid
Consulate Munich
Consulate Mumbai
Consulate Montreal
Consulate Monterrey
Consulate Milan
Consulate Melbourne
Embassy Nicosia
Embassy Niamey
Embassy New Delhi
Embassy Ndjamena
Embassy Nassau
Embassy Nairobi
Consulate Naples
Consulate Naha
Embassy Pristina
Embassy Pretoria
Embassy Prague
Embassy Port Of Spain
Embassy Port Louis
Embassy Port Au Prince
Embassy Phnom Penh
Embassy Paris
Embassy Paramaribo
Embassy Panama
Consulate Peshawar
REO Basrah
Embassy Rome
Embassy Riyadh
Embassy Riga
Embassy Reykjavik
Embassy Rangoon
Embassy Rabat
Consulate Rio De Janeiro
Consulate Recife
Secretary of State
Embassy Suva
Embassy Stockholm
Embassy Sofia
Embassy Skopje
Embassy Singapore
Embassy Seoul
Embassy Sarajevo
Embassy Santo Domingo
Embassy Santiago
Embassy Sanaa
Embassy San Salvador
Embassy San Jose
Consulate Strasbourg
Consulate St Petersburg
Consulate Shenyang
Consulate Shanghai
Consulate Sapporo
Consulate Sao Paulo
Embassy Tunis
Embassy Tripoli
Embassy Tokyo
Embassy The Hague
Embassy Tel Aviv
Embassy Tehran
Embassy Tegucigalpa
Embassy Tbilisi
Embassy Tashkent
Embassy Tallinn
Consulate Toronto
Consulate Tijuana
USUN New York
USEU Brussels
US Office Almaty
US Mission Geneva
US Interests Section Havana
US Delegation, Secretary
UNVIE
Embassy Ulaanbaatar
Embassy Vilnius
Embassy Vienna
Embassy Vatican
Embassy Valletta
Consulate Vladivostok
Consulate Vancouver
Browse by tag
APECO
ASEC
AMGT
AFIN
APER
ACABQ
AORC
AEMR
AF
AE
AR
AGMT
AU
AY
ABLD
AS
AG
AJ
APCS
AX
AM
AMEX
ATRN
ADM
AMED
AFGHANISTAN
AZ
AL
ASUP
AND
ARM
ASEAN
AFFAIRS
AQ
ATFN
AMBASSADOR
AODE
APEC
ACBAQ
AFSI
AFSN
AO
ABUD
AC
ADPM
ADCO
ASIG
ARF
AUC
ASEX
AGAO
AA
AER
AVERY
AGRICULTURE
AIT
AADP
ASCH
AORL
AROC
ACOA
ANET
AID
AMCHAMS
AINF
AMG
AFU
AN
ALOW
ASECKFRDCVISKIRFPHUMSMIGEG
ACS
ADANA
AECL
ACAO
AORG
AGR
BEXP
BR
BM
BG
BL
BA
BTIO
BO
BP
BC
BILAT
BK
BU
BD
BRUSSELS
BB
BF
BBSR
BIDEN
BX
BE
BH
BT
BY
BMGT
BWC
BTIU
BN
CA
CASC
CFED
CO
CH
CS
CU
CE
CI
CM
CMGT
CJAN
COM
CG
CIS
CVIS
CR
CKGR
CHR
CVR
COUNTER
CIA
CLINTON
CY
CPAS
CD
CBW
COUNTERTERRORISM
CITEL
CDG
CW
CODEL
COUNTRY
CLEARANCE
COE
CN
CARICOM
CB
CONDOLEEZZA
CWC
CACS
CSW
CIDA
CIC
CITT
CONS
CL
CACM
CDB
CDC
CAN
CF
CJUS
CTM
CBSA
CARSON
CT
CLMT
CBC
CEUDA
CV
COPUOS
CTR
CROS
CAPC
CAC
CNARC
CICTE
CBE
ECON
ETRD
EIND
ENRG
EC
ELAB
EAGR
EAID
EFIS
EFIN
EINV
EUN
EG
EPET
EAIR
EU
ELTN
EWWT
ECIN
ERD
EI
ETTC
EUR
EN
EZ
ETC
ENVI
EMIN
ET
ENVR
ER
ECPS
EINT
EAP
ES
ENIV
ECONOMY
EXTERNAL
EINN
EFTA
ECONOMIC
EPA
EXBS
ECA
ELN
ETRDEINVECINPGOVCS
ENGR
ECUN
ENGY
ECONOMICS
ELECTIONS
EIAR
EINDETRD
EREL
EUC
ECONEFIN
EURN
EDU
ETRDEINVTINTCS
ECIP
ENERG
EFIM
EAIDS
EK
ETRDECONWTOCS
EINVETC
ECONCS
EUNCH
ESA
ECINECONCS
EUREM
ESENV
EFINECONCS
ETRC
ENNP
EAIG
EXIM
EEPET
EINVECONSENVCSJA
EUMEM
ETRA
ERNG
ETRO
ETRN
EINVEFIN
ICTY
IN
IS
IR
IC
IZ
IA
INTERPOL
IAEA
IT
IMO
IO
IV
ID
IRAQI
IEA
INRB
IL
IWC
ITU
ICAO
ISRAELI
ICRC
IIP
IMF
IBRD
ISLAMISTS
ITALY
ITALIAN
ILO
IPR
IQ
IRS
IAHRC
IZPREL
IRAJ
IDP
ILC
ITF
ICJ
IF
ITPHUM
INMARSAT
ISRAEL
IACI
IBET
ITRA
INR
IRC
IDA
ICTR
IGAD
INRA
INRO
IEFIN
INTELSAT
INTERNAL
INDO
ITPGOV
KWMN
KSCA
KDEM
KTFN
KIPR
KCRM
KPAL
KE
KPAO
KPKO
KS
KN
KISL
KFRD
KJUS
KIRF
KFLO
KG
KTIP
KTER
KRCM
KTIA
KGHG
KIRC
KU
KPRP
KMCA
KMPI
KSEO
KNNP
KZ
KNEI
KCOR
KOMC
KCFC
KSTC
KMDR
KFLU
KSAF
KSEP
KSAC
KR
KGIC
KSUM
KWBG
KCIP
KDRG
KOLY
KAWC
KCHG
KHDP
KRVC
KBIO
KAWK
KGCC
KHLS
KBCT
KPLS
KREL
KCFE
KMFO
KV
KFRDKIRFCVISCMGTKOCIASECPHUMSMIGEG
KFTFN
KVPR
KTDB
KSPR
KIDE
KVRP
KTEX
KBTR
KTRD
KICC
KCOM
KO
KLIG
KDEMAF
KMRS
KRAD
KOCI
KSTH
KUNR
KNSD
KGIT
KFSC
KHIV
KPAI
KICA
KACT
KHUM
KREC
KSEC
KFRDCVISCMGTCASCKOCIASECPHUMSMIGEG
KCMR
KPIN
KESS
KDEV
KNAR
KNUC
KPWR
KENV
KWWMN
KWMNCS
KPRV
KOM
KBTS
KCRS
KNPP
KWNM
KRFD
KVIR
KTBT
KAID
KRIM
KDDG
KRGY
KHSA
KWMM
KMOC
KSCI
KPAK
KX
KPAONZ
KCGC
KID
KPOA
KIFR
KFIN
KWAC
KOMS
KCRCM
KNUP
KMIG
KNNPMNUC
KERG
KTLA
KCSY
KJUST
MOPS
MARR
MASS
MNUC
MX
MCAP
MO
MR
MI
MD
MK
MA
MP
MY
MTCRE
MOPPS
MASC
MIL
MTS
MLS
MILI
MAR
MU
MEPN
MAPP
MTCR
MEPI
MZ
MEETINGS
MG
MW
MAS
MT
MCC
MIK
ML
MARAD
MV
MERCOSUR
MTRE
MPOS
MEPP
MILITARY
MDC
MQADHAFI
MUCN
MRCRE
MAPS
MEDIA
MASSMNUC
MC
NZ
NZUS
NL
NU
NATO
NP
NO
NIPP
NE
NH
NR
NA
NPT
NI
NSF
NG
NSG
NAFTA
NC
NDP
NEW
NRR
NATIONAL
NT
NS
NASA
NAR
NV
NORAD
NSSP
NK
NPA
NGO
NSC
NATOPREL
NW
NPG
NSFO
OPDC
OTRA
OIIP
OREP
OVIP
OSCE
OEXC
OIE
OPRC
OAS
OPIC
OTR
OMIG
OSAC
OFFICIALS
OECD
OSCI
OBSP
OFDA
OPCW
ODIP
OFDP
OES
OPAD
OCII
OHUM
OVP
ON
OIC
OCS
PHUM
PREL
PGOV
PINR
PTER
PARM
PREF
PM
PE
PINS
PK
PHSA
PBTS
PRGOV
PA
PORG
PP
PS
PGOF
PL
PO
PARMS
PKFK
PSOE
PEPR
PAK
POL
PPA
PINT
PMAR
PRELP
PREFA
PALESTINIAN
PBIO
PINF
PNG
PMIL
PFOR
PUNE
PGOVLO
PAO
POLITICS
PHUMBA
PSEPC
PTBS
PCUL
PROP
PNAT
PNR
POLINT
PGOVE
PROG
PHALANAGE
PARTY
PDEM
PECON
PROV
PHUMPREL
PGOC
PY
PCI
PLN
PDOV
PREO
PGIV
PHUH
PAS
PU
POGOV
PF
PINL
POV
PAHO
PRL
PG
PRAM
POLITICAL
PARTIES
POLICY
PGOVSMIGKCRMKWMNPHUMCVISKFRDCA
PGGV
PHUS
PSA
PHUMPGOV
PEL
PSI
PAIGH
POSTS
PBT
PTERE
RS
RU
RW
RM
RO
RP
REGION
RSP
RF
RICE
RCMP
RFE
RIGHTS
RIGHTSPOLMIL
ROBERT
RUPREL
RELATIONS
ROOD
REACTION
RSO
REPORT
SENV
SNAR
SCUL
SR
SC
SOCI
SMIG
SI
SP
SU
SO
SW
SY
SA
SZ
SAN
SF
SN
STEINBERG
SG
ST
SIPDIS
SNARIZ
SNARN
SSA
SK
SPCVIS
SOFA
SAARC
SL
SEVN
SARS
SIPRS
SHUM
SANC
SWE
SHI
SYR
SNARCS
SPCE
SYRIA
SEN
SH
SCRS
SENVKGHG
TRGY
TSPL
TPHY
TSPA
TBIO
TI
TW
THPY
TX
TU
TS
TZ
TC
TH
TT
TIP
TO
TERRORISM
TRSY
TINT
TN
TURKEY
TBID
TL
TV
TNGD
TD
TF
TP
TFIN
TAGS
TK
TR
UNSC
UK
UNGA
UN
US
UNHRC
UG
UP
UNMIK
UNHCR
UE
USTR
UNVIE
UAE
UZ
UY
UNO
UNESCO
USEU
USOAS
UV
UNODC
UNCHS
UNFICYP
UNEP
UNIDROIT
UNDESCO
UNDP
UNPUOS
UNC
UNAUS
USUN
UNCHC
UNCHR
UNCND
UNICEF
UNCSD
UNDC
USNC
USPS
USAID
Browse by classification
Community resources
courage is contagious
Viewing cable 04WELLINGTON900, REVISED PATENT LAW WON'T HELP DRUG INDUSTRY IN
If you are new to these pages, please read an introduction on the structure of a cable as well as how to discuss them with others. See also the FAQs
Understanding cables
Every cable message consists of three parts:
- The top box shows each cables unique reference number, when and by whom it originally was sent, and what its initial classification was.
- The middle box contains the header information that is associated with the cable. It includes information about the receiver(s) as well as a general subject.
- The bottom box presents the body of the cable. The opening can contain a more specific subject, references to other cables (browse by origin to find them) or additional comment. This is followed by the main contents of the cable: a summary, a collection of specific topics and a comment section.
Discussing cables
If you find meaningful or important information in a cable, please link directly to its unique reference number. Linking to a specific paragraph in the body of a cable is also possible by copying the appropriate link (to be found at theparagraph symbol). Please mark messages for social networking services like Twitter with the hash tags #cablegate and a hash containing the reference ID e.g. #04WELLINGTON900.
Reference ID | Created | Released | Classification | Origin |
---|---|---|---|---|
04WELLINGTON900 | 2004-10-28 00:08 | 2011-04-28 00:00 | UNCLASSIFIED//FOR OFFICIAL USE ONLY | Embassy Wellington |
This record is a partial extract of the original cable. The full text of the original cable is not available.
UNCLAS SECTION 01 OF 03 WELLINGTON 000900
SIPDIS
DEPARTMENT FOR EAP/ANP-TRAMSEY, EB/TPP/MTA/IPC-PACETO AND
EB/TPP/BTA/ANA-RARMSTRONG
STATE PASS TO USTR FOR BWEISEL
COMMERCE FOR 4530/ITA/MAC/AP/OSAO/GPAINE
COMMERCE PASS USPTO
SENSITIVE
E.O. 12356: N/A
TAGS: KIPR ECON ETRD NZ
SUBJECT: REVISED PATENT LAW WON'T HELP DRUG INDUSTRY IN
NEW ZEALAND
¶1. (U) Summary: A proposed revision of New Zealand's patent law
will disappoint pharmaceutical companies by failing to extend the
effective patent life of drugs -- stuck at seven years on average
-- and prohibiting patents for methods of medical treatment.
U.S. pharmaceutical firms especially wanted a longer patent term,
which would increase the time they could profit from their
inventions before they faced competition from generics.
¶2. (SBU) U.S. pharmaceutical firm representatives we spoke with
suspect the New Zealand government is not extending the patent
term in order to retain a card to play in possible free-trade
negotiations with the United States. But, the decision also is
consistent with the government's efforts to hold down drug
prices. Policies supporting that objective already have caused
some pharmaceutical firms to leave the New Zealand market and
others to reduce their profile and investments in the country.
The proposed patent amendment will help sustain that trend. End
summary.
Joining the 21st century
------------------------
¶3. (U) Following Cabinet's instructions, the Ministry of Economic
Development is drafting legislation to revise the Patents Act
¶1953. The ministry hopes to publicly release the draft before
the end of the year, with the legislation to be introduced in
Parliament in early 2005, according to a ministry official.
¶4. (U) The revision is intended to bring New Zealand's patent law
into closer conformity with international standards. New Zealand
is one of the few countries that apply a "local novelty standard"
for granting a patent. As the patent law now stands, an
invention is considered new and therefore patentable if no
earlier publication or use had occurred in New Zealand before the
filing of the patent application. The revision would make
patents more difficult to obtain by requiring the invention not
only to be new -- anywhere in the world -- but also to involve an
inventive step, the ministry official said. Taking into account
technological and social changes since 1953, the amended law
would place New Zealand in harmony with its major trading
partners, Australia and the United States, in determining
patentability. The result is that overseas investors and
companies should face fewer barriers to commercial development of
their inventions. About 90 percent of New Zealand patents are
granted to overseas intellectual property owners.
¶5. (U) A review of the Patents Act was initiated in 1989, but was
put on hold in 1990 due to the indigenous Maoris' concerns for
protecting their cultural heritage, according to the ministry
official. The review was reopened in 2000. The resulting
proposed revisions would establish a Maori consultative committee
to advise the patents commissioner on whether an invention
involves traditional knowledge or indigenous plants and animals
or is contrary to Maori values. Patent protection could be
denied if commercial exploitation would be contrary to morality
or public order, to protect human or animal or plant, or to avoid
serious harm to the environment. These provisions could be
applied to genetic material, although such material is not
specifically excluded from patentability. The ministry official
said the exclusions would be allowed under Article 27(2) of the
Agreement on Trade-Related Aspects of Intellectual Property
Rights (TRIPS).
No patents for methods of treatment
-----------------------------------
¶6. (U) The proposed amendment also will exclude from
patentability human beings and methods of treating them.
Publicly, the government has cited ethical reasons for the
exclusions, contending that it would be immoral to constrain for
commercial reasons a doctor's ability to use the best available
methods to treat patients. Privately, the ministry official told
us a primary concern was that patents covering medical methods
could increase public health costs. He said the government was
not convinced that the benefits of such patents would outweigh
their costs.
¶7. (U) The methods-of-treatment exclusion is the government's
response to court decisions saying that the legislature -- not
the judiciary -- had to decide whether such methods could be
patented. In the most recent case, the New Zealand Court of
Appeal ruled June 28 against Pfizer by holding that the Patents
Act 1953 did not cover methods of treating humans. Such methods
thus were not patentable, nor could the court find a basis for
broadening the act's scope, as it had been asked to do by
Pfizer's attorneys.
¶8. (U) Pfizer had filed two patent applications in 1998 for
methods of treating psychotic disorders using a new compound.
Turned down by the patents office, the company took the case to
court. Pfizer had offered to the Court of Appeal to include a
disclaimer relinquishing its right to sue doctors, who otherwise
might face a decision to withhold treatment or risk being sued
for breach of patent. The court said the disclaimer was
inadequate.
¶9. (U) Pfizer has been joined by other drug companies in
contending that the exclusion of methods of treatment from patent
protection could further hinder medical research and development
in New Zealand. With less profit incentive to research
alternative uses of existing drugs, pharmaceutical companies may
forgo the pursuit of other applications in New Zealand.
No change in patent term
------------------------
¶10. (U) The revised law also would keep the maximum patent term
in New Zealand at 20 years, as established by legislation enacted
in 1994. That law, which also abolished patent extensions,
brought New Zealand into line with its TRIPS agreement
obligations. However, of all OECD countries, only New Zealand
and Canada do not provide for patent extensions. Because the
time required to review patent applications is included in the 20-
year term, the pharmaceutical industry contends that the
effective patent life of drugs in New Zealand is about seven
years.
¶11. (U) The industry also points to another provision in New
Zealand law that shortens the time that a company can benefit
from exclusive rights to pharmaceutical products. A December
2002 amendment to the Patents Act allows generic competitors to
engage in "springboarding," or to prepare their product for
market while a proprietary drug is still under patent. This
provision has allowed generic products to enter the market on the
heels of a patent's expiration. No change is expected under the
revised patents law.
¶12. (U) The Cabinet decided in December 2002 to include the issue
of patent term extension for pharmaceuticals in the Patents Act
review. However, in mid-2004, Cabinet -- without explanation --
dropped the issue from an economic study of the Patents Act. The
official from the Ministry of Economic Development told us the
new patents bill would not address the issue.
¶13. (SBU) Although officials have declined to comment on why the
Cabinet nixed a patent extension for pharmaceuticals, some in the
industry have suspicions. Representatives from two U.S.
pharmaceutical companies in August separately told the Consul
General in Auckland that there was strong speculation, backed by
their discussions with high-level government staff, that the
study of pharmaceuticals' patent life had been sidetracked to
give New Zealand "something to trade away" when, or if, New
Zealand was asked to enter free-trade negotiations with the
United States. As it now stands, New Zealand will not even
undertake an analysis of the possible benefits of an extended
patent term for drugs, the drug company representatives
complained.
¶14. (U) The pharmaceutical industry group, Researched Medicines
Industry Association (RMI), asserts that adequate intellectual
property protection is critically important to nurture researched-
based industries in New Zealand. Lesley Clarke, RMI's chief
executive officer, said the length of the patent term is an
important factor weighed by pharmaceutical multinationals in
deciding where to invest in research and site their laboratories.
Comment
-------
¶15. (U) Cost control has long been a primary aim of the New
Zealand government's approach to providing health care to its
citizens. As a result, New Zealand ranks 20th of the 30 OECD
countries in terms of per-capita spending on health. It has
managed to control medical costs in large part by restricting
access by its doctors and their patients to newly introduced
pharmaceuticals and cutting-edge medical treatments. Access has
been limited by slowing the inclusion of new and expensive
pharmaceuticals to a tightly controlled list of approved drugs
for which the government subsidizes costs. The net effect to
drug companies is to hamper their ability to profit from their
inventions. The government's decisions not to extend patent life
or allow patents on medical treatment give the industry yet
another reason to reduce its stake in the country.
¶16. (SBU) Meanwhile, the government has identified the
biotechnology industry as a critical component of its plan for
long-term, sustainable economic growth. At some point, it seems
likely that the government will need to resolve the often
conflicting objectives of its tight-fisted controls on medical
practice and its encouragement of a biotechnology industry.
Until that day arrives, the two goals will share an uneasy co-
existence.
SWINDELLS